In 1989, the World Health Organisation (WHO) recognised and classified Fibromyalgia (FM) and Chronic Fatigue Syndrome, and the scientific community established the disease criteria, including these in the International Classification of Diseases (ICD). FM is classified in the field of rheumatology and the SFC in neurology.
Over the last 15 years, two further Central Sensitivity Syndromes have appeared: Multiple Chemical Sensitivity (MCS) and Electrohypersensitivity (EHS). Their incidence is increasing, and they are closely associated with the other two Central Sensitivity Syndromes. MCS and EHS have been recognised by some countries, but not yet by the WHO. In Spain, since 2014, Multiple Chemical Sensitivity has been classified as a "non-specific allergy". Electrohypersensitivity (EHS), on the other hand, is not currently recognised by the WHO or other countries.
Since 2016, the Catalan government’s Ministry if Health has had a Common Action Plan entitled Central Sensitivity. Hospital Clínic, in Barcelona, has been coordinating the care of Central Sensitivity Diseases in the Barcelona-Esquerra Area (AISBE) as a specialised hospital unit since November 2017.
The fact that these are increasingly recognised as diseases and classified at the international level helps to specify and homogenise their diagnosis, as well as enabling an improved therapeutic approach to each disease.
